Encorafenib/Cetuximab Plus FOLFIRI Prolongs PFS Over SOC in BRAF V600E–Mutant mCRC Read More » March 4, 2026
Giredestrant Plus Everolimus NDA Is Under FDA Review for ESR1-Mutated, ER+ Advanced Breast Cancer Read More » March 4, 2026
FDA Grants Full Approval to Encorafenib Plus Cetuximab/Chemotherapy for BRAF V600E+ mCRC Read More » March 4, 2026
Iza-Bren Yields PFS and OS Benefits vs Chemo in Previously Treated, Advanced TNBC Read More » March 4, 2026
